Therapy Areas: Devices
Vitrolife's EmbryoScope+ receives sales approval in China
18 March 2019 -

Vitrolife AB (STO:VITR), an international medical device company, reported on Friday the receipt of market approval for the time-lapse incubator EmbryoScope+ in China, considered the world's largest market measured in terms of number of IVF treatments.

EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for 15 patients.

According to Vitrolife, it is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos.

The company added that in 2018, it had received market approval in China for the EmbryoScope time-lapse system, with capacity for six patients.

Login
Username:

Password: